
News|Articles|August 5, 2025
From blindness to breakthrough: Milestones that changed ophthalmology forever
Author(s)Martin David Harp
Ophthalmology celebrates 50 years of groundbreaking innovations, highlighting anti-VEGF therapies, OCT imaging, and future advancements in eye care.
Advertisement
Advertisement
In celebration of 50 years of innovation, Ophthalmology Times invited leading experts and rising voices across the field to reflect on the most pivotal advances in eye care. From anti-VEGF therapies to revolutionary imaging tools, the last 5 decades have redefined what’s possible in ophthalmology. What emerged was a striking consensus: Progress has not only preserved vision—it has restored it, streamlined interventions, and deepened our understanding of ocular disease at a cellular level.
Related to this article

Ultra-widefield imaging reveals early retinal risk in pediatric patients.

A successful Type B Rare Disease Evidence Principles meeting confirms the pivotal study design, opening a potential BLA pathway on 6-month efficacy data, with dosing expected to begin in the fourth quarter of 2026.

Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.

Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.

Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.

The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.

Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.
Advertisement
Advertisement

